Hiromitsu Asashima

University of Tsukuba
Country flagJapan

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (20)

Year:

2026

Objectives Rituximab (RTX) is a key treatment for ANCA-associated vasculitis (AAV), but RTX-induced acute thrombocytopenia (RIAT) remains a concern. We aimed to evaluate the risk and risk factors of RIAT in patients with AAV undergoing RTX induction therapy. Methods Patients with new-onset microscopic polyangiitis or granulomatosis with polyangiitis who received RTX in a nationwide multicentre registry in Japan were included. RIAT was defined by platelet count reductions within 28 days post-RTX. Risk factors for RIAT were identified by using logistic regression with stepwise selection, and prediction models were developed. Model performance was assessed using C-statistics. Results Among 175 patients with AAV receiving RTX, RIAT occurred in 35.4% of them. Diabetes mellitus (odds ratio [OR] = 4.96), cardiac disease (OR = 3.57), low platelet count (OR = 1.04 per 104/μl decrease), increased serum creatinine (OR = 1.44 per 1 mg/dl increase), low albumin (OR = 2.33 per 1 g/dl decrease), and high KL-6 (OR = 1.09 per 100 U/ml increase) were identified as significant predictors. A predictive model incorporating these factors achieved a C-statistic of 0.817. Conclusion RIAT is a frequent complication of RTX induction in patients with AAV, with diabetes mellitus and cardiac disease being strong risk factors. Our predictive model enables risk assessment for RIAT, allowing clinicians to optimize treatment strategies.

Year:

2026

Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by multiple organ involvement. It is known that cytokines produced from activated CD4+ T cells play a pivotal role in the development of SLE; however, the details of pathological processes remain unclear. The purpose of this study is to elucidate the role of activated CD4+ T cells on the pathogenesis of lupus using SLE murine models induced by toll like receptor 7 agonist imiquimod (IMQ). Lupus was induced in wild-type (WT) and interferon γ (IFNγ)-deficient (IFNγ−/−) mice by topical IMQ treatment. Splenic T and B cell subsets were analyzed by flow cytometry. CD4+ T cells and B cells were isolated for co-culture to assess B cell differentiation and IgG production. Comprehensive lupus-like phenotypes were evaluated. Single-cell RNA sequencing (scRNA-seq) was performed to characterize IFNγ-associated cellular and molecular pathways. IMQ treatment increased IFNγ-producing CD4+ T cells, along with Tfh cells, Tph cells, age-associated B cells, and plasma cells in WT mice. CD4+ T cells from IMQ-treated WT mice promoted B-cell differentiation and IgG production in co-culture assays. In IFNγ−/− mice, lupus-like phenotypes were significantly attenuated, and co-cultured B cells showed reduced differentiation and IgG production. Single-cell RNA sequencing revealed that IFNγ plays a critical role in promoting B cell differentiation and autoantibody production. IFNγ derived from activated CD4+ T cells plays a critical role in driving B-cell differentiation and promoting autoantibody production in IMQ-induced lupus.

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Objective To clarify T/B cell-specific gene expression patterns using RNA-Seq in IgG4-related disease (IgG4-RD). Methods Pathologically confirmed submandibular gland (SMG) (n = 3) and peripheral blood mononuclear cells (PBMC) (n = 4) from four treatment-naïve patients with definite IgG4-RD, as well as PBMCs from primary Sjögren syndrome (pSS) (n = 3) and healthy controls (HCs) (n = 3), were collected, and subsequently Pan T and CD19+ B cells were sorted. We conducted RNA sequencing to compare the gene expressions of Pan T and CD19+ B cells in SMGs and PBMCs in IgG4-RD or IgG4-RD versus pSS and HCs in PBMCs. Ingenuity pathway analysis (IPA) and qPCR validation were performed for differentially expressed genes (DEGs). Results Principal component analysis (PCA) results showed the gene expression patterns of Pan T and CD19+ B cells derived from SMGs differed from those derived from PBMCs in IgG4-RD. However, the gene expression patterns of Pan T and CD19+ B cells derived from PBMCs were not clustered between groups. A total of 214 upregulated and 50 downregulated DEGs in Pan T cells and 630 upregulated and 109 downregulated DEGs in CD19+ B cells were identified in SMGs compared with PBMCs in IgG4-RD. The upregulated DEGs in SMGs of IgG4-RD included cytokines, chemokines, and transcription regulators. IPA for these DEGs clarified immune system-related pathways were positively regulated in SMGs compared with PBMCs in IgG4-RD. Quantitative PCR validated significantly increased mRNA expression of IL-21 and EGR2 by Pan T cells in SMGs compared with PBMCs of IgG4-RD. Conclusion RNA-Seq clarified the DEGs of Pan T and CD19+ B cells from SMGs in comparison with PBMCs, which might contribute to the pathogenesis of IgG4-RD.

Year:

2026

Coronavirus disease 2019 (COVID-19) poses significant risks for solid organ transplant recipients, who have atypical but poorly characterized immune responses to infection. We aim to understand the host immunologic and microbial features of COVID-19 in transplant recipients by leveraging a prospective multicenter cohort of 86 transplant recipients age- and sex-matched with 172 non-transplant controls. We find that transplant recipients have higher nasal SARS-CoV-2 viral abundance and impaired viral clearance, and lower anti-spike IgG levels. In addition, transplant recipients exhibit decreased plasmablasts and transitional B cells, and increased senescent T cells. Blood and nasal transcriptional profiling demonstrate unexpected upregulation of innate immune signaling pathways and increased levels of several proinflammatory serum chemokines. Severe disease in transplant recipients, however, is characterized by a less robust induction of pro-inflammatory genes and chemokines. Together, our study reveals distinct immune features and altered viral dynamics in solid organ transplant recipients.

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (40)

Holden T. Maecker

Stanford University School of Medicine

UNITED STATES
View details

Suzanna Chak

University of California, San Francisco

UNITED STATES
View details

Elsio Wunder

Assistant Professor

University of Connecticut

UNITED STATES
View details

Slim Fourati

Assistant Professor

Northwestern University Feinberg School of Medicine

UNITED STATES
View details

Bali Pulendran

Emory University

UNITED STATES
View details

Justin Rousseau

Associate Professor

University of Texas Southwestern Medical Center

UNITED STATES
View details

Samuel Yang

Faculty

Stanford University

UNITED STATES
View details

Mehmet Saluvan

Sr. Staff Scientist

Boston Children's Hospital

UNITED STATES
View details

Yoshia Miyawaki

Special-Appointment Assistant Professor

Okayama Daigaku

JAPAN
View details

Joann Diray Arce

Assistant Professor

Boston Children's Hospital

UNITED STATES
View details

Albert Ko

Professor of Medicine

Yale University

UNITED STATES
View details

Kazushi Maruo

Associate professor

University of Tsukuba

JAPAN
View details

Alvin Kho

Assistant Professor

Harvard University

UNITED STATES
View details

Ramin Salehi-Rad

UCLA

UNITED STATES
View details

Catherine Blish

Association Professor

Stanford University School of Medicine

UNITED STATES
View details

Akiko Iwasaki

Professor

Yale University School of Medicine

UNITED STATES
View details

Scott Brakenridge

Professor

University of Washington

UNITED STATES
View details

Farrah Kheradmand

Professor

Baylor College of Medicine

UNITED STATES
View details

Michael Wilson

Professor

University of California, San Francisco

UNITED STATES
View details

Isao Matsumoto

Professor

University of Tsukuba

JAPAN
View details

Cole Maguire

University of Texas at Austin

UNITED STATES
View details

Harm van Bakel

Associate Professor

Icahn School of Medicine at Mount Sinai

UNITED STATES
View details

三木 春香

Associate Professor

University of Tsukuba

JAPAN
View details

Al Ozonoff

Associate Professor

Harvard University

UNITED STATES
View details

Linda N. Geng

Stanford University

UNITED STATES
View details

John Greenland

Associate Professor

UCSF Medical Center

UNITED STATES
View details

Toshiko Ito-Ihara

Specially Appointed Professor

Kyoto Prefectural University of Medicine

JAPAN
View details

Lekshmi Santhosh

Associate Professor

University of California

UNITED STATES
View details

Aleksandra Leligdowicz

Assistant Professor

University of Western Ontario

CANADA
View details

anil sapru

Professor

University of California

UNITED STATES
View details

Mary Ann Comunale

Assistant Professor

Drexel University College of Medicine

UNITED STATES
View details

Angela Rogers

Professor

University of Texas Southwestern Medical Center

UNITED STATES
View details

Masaru Shimizu

Specially Appointed Lecturer

University of Tsukuba

JAPAN
View details

George A Yendewa

Assistant Professor

Case Western Reserve University School of Medicine

UNITED STATES
View details

Nathan Grubaugh

Associate Professor

Yale School of Public Health

UNITED STATES
View details

Yuya Kondo

Lecturer

University of Tsukuba

JAPAN
View details

Michele Kutzler

Professor of Medicine and Microbiology and Immunology

Drexel University

UNITED STATES
View details

Boryana Petrova

Head of Research Metabolomics

Medical University of Vienna

AUSTRIA
View details

Erin Scherer

Associate Professor

Emory University

UNITED STATES
View details

Edward Vincent S. Faustino

Professor of Pediatrics (Critical Care)

Yale University School of Medicine

UNITED STATES
View details